EasySep™ Release 人APC正选试剂盒

采用磁珠解离技术，对来源于人外周血单个核细胞或洗涤后白细胞分离样本中标记 APC 偶联抗体的细胞进行免疫磁珠正选分离，分离后的细胞上无磁珠

只有 %1 左

率先评论此产品

¥11,648.00

产品号 #（选择产品）

产品号 #100-0031_C

采用可解离磁珠技术的免疫磁珠正选试剂盒

产品优势

在40分钟内从人样本中分选出用APC偶联抗体标记的高纯度细胞
无需清洗去除EasySep™ Releasable RapidSpheres™可解离磁珠

产品组分包括

EasySep™ Release 人APC正选试剂盒（产品号 #100-0031）
- EasySep™ Release APC正选抗体混合物，1 mL
- EasySep™ Releasable RapidSpheres™磁珠，1 mL
- EasySep™Release 缓冲液（浓缩），3 x 1 mL
- 用于正选的抗人CD32阻断剂，1 mL

立即询价

总览

使用EasySep™可解离APC正选试剂盒，可从新鲜或冻存的人外周血单个核细胞（PBMCs）或其他单细胞悬液中，通过免疫磁性正选法分离高纯度藻蓝蛋白（APC）偶联抗体标记的细胞。EasySep™技术在已发表的研究中被广泛应用超过20年，将单克隆抗体的特异性与无柱磁分离系统的简便性相结合。

该EasySep™正选步骤包括使用可识别APC的抗体复合物和EasySep™可解离RapidSpheres™对目标细胞进行标记。与传统磁性颗粒始终结合在目标细胞上的方式不同，该试剂盒中的RapidSpheres™具有可解离特性。目标细胞首先被抗体和这些特殊的磁性颗粒标记，然后使用EasySep™磁极在无柱的情况下进行分离。非目标细胞被简单地倒出，而目标细胞保留在试管中。随后，使用解离剂从EasySep™分离的APC偶联抗体标记细胞中去除结合在细胞表面的磁性颗粒。

使用此EasySep™解离试剂盒进行磁性细胞分离后，目标细胞可立即用于下游应用，如流式细胞术、细胞培养或DNA/RNA提取。抗体复合物仍结合在目标细胞表面，可能与Brilliant Violet™抗体偶联物、聚乙二醇修饰蛋白或其他化学相关配体发生相互作用。了解更多关于免疫磁性EasySep™技术的工作原理。探索更多产品，包括培养基、添加剂、抗体等，为您的实验流程提供优化方案。

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

文献 (3)

FOXO1 is a master regulator of memory programming in CAR T cells Nature 2024 Apr

Abstract

A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persistence in patients and clinical efficacy2–6,suggesting that memory programs may underpin durable CAR T cell function. Here we show that the transcription factor FOXO1 is responsible for promoting memory and restraining exhaustion in human CAR T cells. Pharmacological inhibition or gene editing of endogenous FOXO1 diminished the expression of memory-associated genes,promoted an exhaustion-like phenotype and impaired the antitumour activity of CAR T cells. Overexpression of FOXO1 induced a gene-expression program consistent with T cell memory and increased chromatin accessibility at FOXO1-binding motifs. CAR T cells that overexpressed FOXO1 retained their function,memory potential and metabolic fitness in settings of chronic stimulation,and exhibited enhanced persistence and tumour control in vivo. By contrast,overexpression of TCF1 (encoded by TCF7) did not enforce canonical memory programs or enhance the potency of CAR T cells. Notably,FOXO1 activity correlated with positive clinical outcomes of patients treated with CAR T cells or tumour-infiltrating lymphocytes,underscoring the clinical relevance of FOXO1 in cancer immunotherapy. Our results show that overexpressing FOXO1 can increase the antitumour activity of human CAR T cells,and highlight memory reprogramming as a broadly applicable approach for optimizing therapeutic T cell states. The transcription factor FOXO1 has a key role in human T cell memory,and manipulating FOXO1 expression could provide a way to enhance CAR T cell therapies by increasing CAR T cell persistence and antitumour activity.

View publication

Single-cell analysis reveals CD34+CD90+ endothelial cells promote tumor metastasis in gallbladder cancer M. Hou et al. NPJ Precision Oncology 2025 Jul

Abstract

Gallbladder cancer (GBC) is the most common malignancy of the biliary tract,with high metastasis incidence and extremely low survival rate. The tumor endothelial cells (TECs) are fundamental components in the tumor microenvironment and significantly contribute to various tumor progression; however,the roles of TECs in GBC are poorly understood. Here,using single-cell RNA sequencing,we identify a GBC-enriched endothelial population-CD34+CD90+ ECs (SAEndo2). The CD34+CD90+ endothelial subset correlates with patients’ poor prognosis and liver metastasis. In vitro and in vivo experiments suggest that CD34+CD90+ ECs promote the GBC cell migration and metastasis,showing EndoMT properties. Moreover,CD34+CD90+ ECs display enhanced activation of TGF-β signaling,and TGF-β inhibition abolishes the CD34+CD90+ ECs’ promotion effect on GBC cell migration. Collectively,our study provides a detailed profiling of endothelial cells in GBC and identifies an essential endothelial population that regulates GBC metastasis,laying new theoretical insight and offering a potential therapeutic target for GBC metastasis.

View publication

Circulating CD137⁺Treg cells and LOX-1⁺PMN-MDSCs as biomarkers of immunotherapy resistance in (R/M) HNSCC patients A. Asquino et al. Journal of Experimental & Clinical Cancer Research : CR 2025 Dec

Abstract

Background: Recurrent/metastatic head and neck squamous cell carcinoma ((R/M) HNSCC) represents one of the most aggressive and immunosuppressive cancers. Despite the introduction of immune checkpoint inhibitors (ICIs),only a limited number of patients obtain long-term benefits. In (R/M) HNSCC patients,the antitumor immune response is defective,conferring resistance and promoting tumor progression. Therefore,the identification of novel biomarkers for superior clinical outcomes and easily accessible in standard clinical settings is still an unmet clinical need. Methods: Blood liquid biopsies obtained from (R/M) HNSCC patients undergoing pembrolizumab therapy (monotherapy or in combination with chemotherapy) were analyzed by flow cytometry to evaluate the levels of circulating immunosuppressive regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs),at baseline and during therapy. Correlations between these immunosuppressive immune cell subsets and clinical parameters (clinical response rate,progression-free survival (PFS),overall survival (OS) and performance status (PS)) were performed. Results: Univariate analysis showed that before therapy,higher circulating levels of both CD137⁺Tregs and LOX-1⁺PMN-MDSCs,identified patients with significantly worse survival. Furthermore,CD137⁺Tregs resulted also positively correlated with worse PS,while high levels of LOX-1⁺PMN-MDSCs negatively affected response to pembrolizumab,with a significant increase in non-responsive patients during therapy. Interestingly,both CD137⁺Tregs as well as LOX-1⁺PMN-MDSCs exerted a higher immunosuppression on T cell proliferation than CD137−Tregs and LOX-1⁻PMN-MDSCs,respectively. Multivariate analysis revealed that the circulating LOX-1⁺PMN-MDSC subset resulted as an independent prognostic factor for survival by multivariate analysis,as confirmed in an independent validation cohort. Conclusions: The levels of blood circulating LOX-1⁺PMN-MDSCs may be proposed as non-invasive biomarkers to predict clinical outcomes of (R/M) HNSCC patients developing resistance to immunotherapy,improving patient selection and suggesting novel personalized therapies.

View publication

View All Publications

更多信息

更多信息
物种	人
Magnet Compatibility	• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001) • EasyEights™ EasySep™ Magnet (Catalog #18103) • EasyPlate™ EasySep™ Magnet (Catalog #18102)
样本来源	PBMC, 其它细胞系, 白细胞单采术样本
Selection Method	Positive

EasySep™ Release 人APC正选试剂盒

产品号 #100-0031

产品号 #（选择产品）

产品号 #100-0031_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

EasySep™ Release 人APC正选试剂盒

产品号 #100-0031

产品号 #（选择产品）

产品号 #100-0031_C

产品优势

产品组分包括

总览

实验数据

产品说明书及文档

相关材料与文献

技术资料 (8)

文献 (3)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台